Headache News and Research

Latest Headache News and Research

FDA approves Yondelis (trabectedin) for treatment of specific soft tissue sarcomas

The U.S. Food and Drug Administration today approved Yondelis (trabectedin), a chemotherapy, for the treatment of specific soft tissue sarcomas (STS) – liposarcoma and leiomyosarcoma – that cannot be removed by surgery (unresectable) or is advanced (metastatic).

24 Oct 2015

Takeda highlights safety, efficacy of vedolizumab for UC and CD at ACG Annual Scientific Meeting

Takeda Pharmaceuticals, U.S.A., Inc., today announced that data highlighting the efficacy and safety of vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD), will be presented during the 2015 American College of Gastroenterology Annual Scientific Meeting in Honolulu, Hawaii, held on October 16-21.

20 Oct 2015

FDA grants accelerated approval to Praxbind (idarucizumab)

The U.S. Food and Drug Administration today granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa's blood-thinning effects.

19 Oct 2015

Boehringer Ingelheim announces FDA approval of Praxbind (idarucizumab)

Boehringer Ingelheim Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration granted approval of Praxbind (idarucizumab). PRAXBIND is indicated for patients treated with Pradaxa (dabigatran etexilate mesylate), when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding.

16 Oct 2015

BDSI announces FDA approval of BUNAVAIL sNDA for manufacturing specification change

BioDelivery Sciences International, Inc. announced that the U.S. Food and Drug Administration has approved the company's Supplemental New Drug Application (sNDA) for a manufacturing specification change for BUNAVAIL (buprenorphine and naloxone) buccal film (CIII).

15 Oct 2015

Boehringer Ingelheim, Lilly announce availability of Synjardy tablets in U.S. pharmacies

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced that Synjardy (empagliflozin/metformin hydrochloride) tablets are now available by prescription in pharmacies across the United States.

14 Oct 2015

Data shows romosozumab better than teriparatide in increasing bone strength in postmenopausal women

Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today presented additional findings from an exploratory sub-study of the previously reported romosozumab Phase 2 trial.

13 Oct 2015

Mysterious kidney disease may be caused by chronic dehydration tied to global climate change

A mysterious kidney disease that has killed over 20,000 people in Central America, most of them sugar cane workers, may be caused by chronic, severe dehydration linked to global climate change, according to a new study by Richard J. Johnson, MD, of the University of Colorado Anschutz Medical Campus.

9 Oct 2015

ASA: Epidural or spinal anesthesia preferred for most cesarean deliveries

New research could ease the minds of expectant mothers who may be nervous about epidurals or spinal anesthesia for childbirth. A study of New York state hospitals, published in the Online First edition of Anesthesiology, the official medical journal of the American Society of Anesthesiologists, found the rate of anesthesia-related complications in women who received epidural or spinal anesthesia for cesarean delivery decreased 25 percent over the past decade.

9 Oct 2015

ED physicians make key changes in clinical decision-making after viewing CT scan results

A study from the Massachusetts General Hospital Institute for Technology assessment finds that, after viewing CT scan results, physicians in the emergency departments of four major academic medical centers made key changes in clinical decision-making for patients with symptoms frequently seen in emergency rooms.

9 Oct 2015

Daclizumab HYP superior to interferon in relapsing–remitting MS

The DECIDE study shows that 4-weekly daclizumab high-yield process reduces disease activity in patients with relapsing–remitting multiple sclerosis more effectively than weekly interferon beta-1a, albeit at the cost of more adverse effects.

8 Oct 2015

FDA grants 12-year exclusivity to RUCONEST (C1 esterase inhibitor [recombinant])

Salix Pharmaceuticals and Pharming Group NV announced today that the U.S. Food and Drug Administration has granted 12 years of exclusivity to RUCONEST (C1 esterase inhibitor [recombinant]) 50 IU/kg.

8 Oct 2015

Phase II psoriasis study shows efficacy of Boehringer Ingelheim's BI 655066 over ustekinumab

New results from a Phase II head-to-head psoriasis study showed superior efficacy of Boehringer Ingelheim's investigational biologic compound BI 655066, over ustekinumab. After nine months, 69 percent of patients with moderate-to-severe plaque psoriasis maintained clear or almost clear skin (PASI 90) with BI 655066 in the higher dose group compared to 30 percent of patients on ustekinumab.

8 Oct 2015

Allergan's anti-infective portfolio to be highlighted at IDWeek 2015

Allergan plc today announced that its infectious disease portfolio will be featured in 13 abstracts highlighting data at IDWeek 2015, which takes place from October 7-11, 2015, in San Diego.

8 Oct 2015

NS1 protein can be considered as vital target for development of new drugs to treat dengue: Study

Dengue is a mosquito-borne tropical disease currently endemic in more than 10 countries. According to the World Health Organization, 390 million people are infected by dengue every year.

7 Oct 2015

Calcitonin-gene related peptide antibody inhibition shows migraine prevention promise

TEV-48125, a monoclonal anti-calcitonin-gene related peptide antibody, is well tolerated and effective in the prevention of high-frequency episodic migraine and chronic migraine, findings from two phase IIb studies show.

2 Oct 2015

One-third of people living with diabetes fail to report night-time hypoglycaemia to their doctor, shows research

A new survey reports that one-third (32%) of people living with diabetes failed to report night-time hypoglycaemia to their doctor or nurse despite the impact they have on the lives of people living with the condition.

1 Oct 2015

Brodalumab therapy achieves 100% reduction in psoriasis symptoms

An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers and published online today in the New England Journal of Medicine.

1 Oct 2015

Risks of water intoxication increase as outdoor endurance recreation grows in popularity

While emphasis is often placed on keeping athletes and outdoor enthusiasts properly hydrated, too much water can be just as dangerous. Exercise-associated hyponatremia (EAH), also known as water intoxication, results in an extreme, and potentially fatal, sodium imbalance.

30 Sep 2015

Teva presents new Reslizumab data at European Respiratory Society (ERS) International Congress 2015

Teva Pharmaceutical Industries Ltd., has presented results from a post hoc analysis of two pivotal Phase III clinical trials showing that treatment with reslizumab reduced clinical asthma exacerbations (CAEs) by 75 percent versus placebo in a subgroup of patients with late onset asthma (diagnosed at 40 years of age and older) with elevated blood eosinophils, who were inadequately controlled on inhaled corticosteroids (ICS).

28 Sep 2015

Headache News and Research

Latest Headache News and Research

FDA approves Yondelis (trabectedin) for treatment of specific soft tissue sarcomas

Takeda highlights safety, efficacy of vedolizumab for UC and CD at ACG Annual Scientific Meeting

FDA grants accelerated approval to Praxbind (idarucizumab)

Boehringer Ingelheim announces FDA approval of Praxbind (idarucizumab)

BDSI announces FDA approval of BUNAVAIL sNDA for manufacturing specification change

Boehringer Ingelheim, Lilly announce availability of Synjardy tablets in U.S. pharmacies

Data shows romosozumab better than teriparatide in increasing bone strength in postmenopausal women

Mysterious kidney disease may be caused by chronic dehydration tied to global climate change

ASA: Epidural or spinal anesthesia preferred for most cesarean deliveries

ED physicians make key changes in clinical decision-making after viewing CT scan results

Daclizumab HYP superior to interferon in relapsing–remitting MS

FDA grants 12-year exclusivity to RUCONEST (C1 esterase inhibitor [recombinant])

Phase II psoriasis study shows efficacy of Boehringer Ingelheim's BI 655066 over ustekinumab

Allergan's anti-infective portfolio to be highlighted at IDWeek 2015

NS1 protein can be considered as vital target for development of new drugs to treat dengue: Study

Calcitonin-gene related peptide antibody inhibition shows migraine prevention promise

One-third of people living with diabetes fail to report night-time hypoglycaemia to their doctor, shows research

Brodalumab therapy achieves 100% reduction in psoriasis symptoms

Risks of water intoxication increase as outdoor endurance recreation grows in popularity

Teva presents new Reslizumab data at European Respiratory Society (ERS) International Congress 2015

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Headache News and Research

Latest Headache News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in